• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OneMedNet Corp filed SEC Form 8-K: Financial Statements and Exhibits

    9/12/24 4:15:40 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ONMD alert in real time by email
    false 0001849380 0001849380 2024-09-09 2024-09-09 0001849380 ONMD:CommonStock0.0001ParValuePerShareMember 2024-09-09 2024-09-09 0001849380 ONMD:RedeemableWarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2024-09-09 2024-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 9, 2024

     

    ONEMEDNET CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40386   86-2076743

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    6385 Old Shady Oak Road, Suite 250

    Eden Prairie, MN 55344

    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: 800-918-7189

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share   ONMD   The Nasdaq Stock Market LLC
             
    Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share   ONMDW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01.

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On September 9, 2024, OneMedNet Corporation (the “Company”) received an expected delinquency notification letter (the “First Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”) by the applicable due date, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).

     

    On September 10, 2024, the Company received a notification letter (the “Second Notice” and together with the First Notice, the “Notices”) from Nasdaq, which responded to the Company’s plan to regain compliance regarding its delinquent Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Initial Delinquent Filing” and together with the Form 10-Q, the “Delinquent Filings”). In the Second Notice, Nasdaq grants the Company an exception until October 31, 2024 to file the Delinquent Filings with the SEC and regain compliance with the Rule. In the event the Company does not regain compliance with the Rule by October 31, 2024, Nasdaq will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a hearings panel.

     

    Neither the Notices nor the Company’s noncompliance with the Rule has an immediate effect on the listing or trading of the Company’s securities on Nasdaq, which will continue to trade on The Nasdaq Capital Market under the symbol “ONMD.” The Company continues to work diligently to complete the Delinquent Filings and plans to file the same as promptly as possible to regain compliance with the Rule. The Company currently expects to prepare and file the Delinquent Filings on or before October 31, 2024, although there can be no guarantee that the Delinquent Filings are filed within the required timeframe.

     

    As required under Nasdaq Listing Rule 5810(b), the Company issued a press release on September 12, 2024, announcing that it had received the First Notice, its plan for compliance and other matters. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.

     

    Description

    99.1   Press Release dated September 12, 2024.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: September 12, 2024

     

      ONEMEDNET CORPORATION
       
      By: /s/ Aaron Green
        Aaron Green
        Chief Executive Officer

     

     

     

    Get the next $ONMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), today announced record bookings in 2025 of data-delivery agreements totaling $2.79 million of contract value, exceeding 2024 bookings by more than four times (4X). The milestone reflects increasing deal size, strong enterprise demand, and meaningful progress toward a recurring subscription model. The Company also provides an update on product offering heading into 2026. 2025 Booking Highlights Total Bookings: $2.79 million in contract value signed in 2025, 4.1X more than prior fiscal yearLarger Deal Sizes:

    2/12/26 9:00:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. Thi

    1/27/26 10:14:00 AM ET
    $BFLY
    $NNOX
    $ONMD
    Medical Electronics
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Medical Specialities

    OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software

    MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans. Scaida BrainCT-ICH leverages artificial intelligence to analyze head CT images and identify suspected intracranial hemorrhage in approximately 5.97 seconds after image acquisition, enabling faster clinical tria

    1/22/26 9:00:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Green Aaron sold $218,625 worth of shares (126,322 units at $1.73), decreasing direct ownership by 7% to 1,804,103 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    12/23/25 8:00:03 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    SEC Filings

    View All

    OneMedNet Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - OneMedNet Corp (0001849380) (Filer)

    12/23/25 5:00:40 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by OneMedNet Corp

    SCHEDULE 13G/A - OneMedNet Corp (0001849380) (Subject)

    11/14/25 5:27:22 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B3 filed by OneMedNet Corp

    424B3 - OneMedNet Corp (0001849380) (Filer)

    11/14/25 5:26:23 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Casaburi Eric bought $39,262 worth of shares (20,475 units at $1.92) and was granted 90,000 shares (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:54:45 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

    MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare

    12/2/24 8:30:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet appoints new CFO

    MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde

    9/10/24 8:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    11/12/24 3:35:37 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    10/1/24 5:01:18 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    8/5/24 5:15:39 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Financials

    Live finance-specific insights

    View All

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

    MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million. Additional discounted debt settl

    8/14/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care